Wegovy Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Access in 2026
Wegovy (semaglutide 2.4 mg) prescribing information: FDA approved June 4, 2021; EMA authorized January 6, 2022; cardiovascular indication added March 2024.